Dova's thrombocytopenia drug wins FDA approval

FDA approved Doptelet avatrombopag from the AkaRx Inc. subsidiary of Dova Pharmaceuticals Inc. (NASDAQ:DOVA) to treat thrombocytopenia in adults with chronic liver disease who are scheduled

Read the full 266 word article

User Sign In